Avinger (NASDAQ:AVGR) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report released on Friday, Zacks.com reports. The brokerage presently has a $1.00 target price on the medical device company’s stock. Zacks Investment Research‘s target price suggests a potential upside of 21.30% from the company’s previous close.
According to Zacks, “Avinger, Inc. is engaged in designing, manufacturing and selling image-guided, catheter-based systems to treat peripheral arterial disease. The company’s product consists of Lightbox imaging console, Wildcat, Kittycat, Ocelot, Ocelot PIXL, Ocelot MVRX and Juicebox. Avinger, Inc. is based in Redwood City, California. “
Separately, B. Riley reissued a “buy” rating and issued a $2.50 price target on shares of Avinger in a report on Wednesday, September 1st.
Avinger (NASDAQ:AVGR) last issued its quarterly earnings results on Monday, August 9th. The medical device company reported ($0.04) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.04). Avinger had a negative net margin of 160.26% and a negative return on equity of 102.07%. On average, sell-side analysts expect that Avinger will post -0.23 EPS for the current year.
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Citadel Advisors LLC acquired a new stake in Avinger during the 1st quarter worth $128,000. Commonwealth Equity Services LLC grew its holdings in Avinger by 335.8% during the 1st quarter. Commonwealth Equity Services LLC now owns 75,272 shares of the medical device company’s stock worth $113,000 after acquiring an additional 58,000 shares during the period. State Street Corp bought a new position in shares of Avinger during the second quarter worth $423,000. Renaissance Technologies LLC bought a new position in shares of Avinger during the second quarter worth $376,000. Finally, Squarepoint Ops LLC bought a new position in shares of Avinger during the second quarter worth $141,000. 11.53% of the stock is owned by hedge funds and other institutional investors.
Avinger, Inc is a commercial-stage medical device company, which engages in the designs, manufactures and sells image-guided, catheter-based systems that are used by physicians to treat patients with peripheral artery disease. Its products include Pantheris, Lightbox, Ocelot, Wildcat, Juicebox, and Kittycat.
Featured Story: Stock Symbols, CUSIP and Other Stock Identifiers
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Avinger Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avinger and related companies with MarketBeat.com's FREE daily email newsletter.